Vaccinations with Recombinant Variants of Aspergillus fumigatus Allergen Asp f 3 Protect Mice against Invasive Aspergillosis
- 1 September 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (9), 5075-5084
- https://doi.org/10.1128/iai.00815-06
Abstract
A vaccine that effectively protects immunocompromised patients against invasive aspergillosis is a novel approach to a universally fatal disease. Here we present a rationale for selection and in vivo testing of potential protein vaccine candidates, based on the modification of an immunodominant fungal allergen for which we demonstrate immunoprotective properties. Pulmonary exposure to viable Aspergillus fumigatus conidia as well as vaccination with crude hyphal extracts protects corticosteroid-immunosuppressed mice against invasive aspergillosis (J. I. Ito and J. M. Lyons, J. Infect. Dis. 186:869-871, 2002). Sera from the latter animals contain antibodies with numerous and diverse antigen specificities, whereas sera from conidium-exposed mice contain antibodies predominantly against allergen Asp f 3 (and some against Asp f 1), as identified by mass spectrometry. Subcutaneous immunization with recombinant Asp f 3 (rAsp f 3) but not with Asp f 1 was protective. The lungs of Asp f 3-vaccinated survivors were free of hyphae and showed only a patchy low-density infiltrate of mononuclear cells. In contrast, the nonimmunized animals died with invasive hyphal elements and a compact peribronchial infiltrate of predominantly polymorphonuclear leukocytes. Three truncated versions of rAsp f 3, spanning amino acid residues 15 to 168 [rAsp f 3(15-168)], 1 to 142, and 15 to 142 and lacking the known bipartite sequence required for IgE binding, were also shown to be protective. Remarkably, vaccination with either rAsp f 3(1-142) or rAsp f 3(15-168) drastically diminished the production of antigen-specific antibodies compared to vaccination with the full-length rAsp f 3(1-168) or the double-truncated rAsp f 3(15-142) version. Our findings point to a possible mechanism in which Asp f 3 vaccination induces a cellular immune response that upon infection results in the activation of lymphocytes that in turn enhances and/or restores the function of corticosteroid-suppressed macrophages to clear fungal elements in the lungs.Keywords
This publication has 47 references indexed in Scilit:
- Protein Expression Profiling of Coccidioides posadasii by Two-Dimensional Differential In-Gel Electrophoresis and Evaluation of a Newly Recognized Peroxisomal Matrix Protein as a Recombinant Vaccine CandidateInfection and Immunity, 2006
- Immunotherapy for Fungal InfectionsClinical Infectious Diseases, 2006
- A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primatesVaccine, 2005
- Vaccinate Against Aspergillosis! A Call to Arms of the Immune SystemClinical Infectious Diseases, 2004
- Reverse Vaccinology and GenomicsScience, 2003
- New antifungal agentsDermatologic Clinics, 2003
- Regulation by Granulocyte‐Macrophage Colony‐Stimulating Factor and/or Steroids Given In Vivo of Proinflammatory Cytokine and Chemokine Production by Bronchoalveolar Macrophages in Response toAspergillusConidiaThe Journal of Infectious Diseases, 2003
- Use of Recombinant Mitogillin for Improved Serodiagnosis ofAspergillus fumigatus-Associated DiseasesJournal of Clinical Microbiology, 2001
- Opportunistic CNS infection after bone marrow transplantationBone Marrow Transplantation, 1999
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976